Abstract: Improved understanding of the multiple myeloma biology along with the discovery of novel anti-myeloma agents has led to a better-quality treatment of these patients. Multiple myeloma can cause a variety of complications such as hyperviscosity syndrome, hypercalcaemia, spinal cord compression, early infection, bone disease and renal impairment, some of which are life-treatening. Treatment of these has been demonstrated to significantly reduce morbidity and early fatal outcome. Utilization of novel agents including: Thalidomide, Bortezomib and Lenalidomide as part of the induction protocols before autologous stem cell transplantation (ASCT) and also as a front-line treatment in older patients, has been shown to be superior in comparison with the previous treatment strategies. The latter has been confirmed regarding the overall treatment response, progression-free survival and even better overall survival in some studies. Greater experience in dosing of these medications has led to a decrease in the toxicity of the protocols. A third phase clinical study has demonstrated a better clinical outcome when Bortezomib was used prior ASCT. Furthermore, involvement of these agents in the post-transplant consolidation and maintenance treatments has been shown to be beneficial in other aspects such as prolongation of progression-free survival. The immune therapy represents a potentially promising treatment modality. Daratumumab is a new, specific, human monoclonal antibody with high affinity to a unique epitope on CD38. It induces plasma cells death through several immunological mechanisms. It has a good safety profile and a substantially activity as a single-agent therapy in refractory and relapsed myeloma.
Introduction
Multiple myeloma is a malignant disorder of plasma cells, characterized by uncontrolled and progressive proliferation of a single clone of plasma cells. The disease leads to progressive morbidity and eventual mortality by lowering resistance to infection and causing significant skeletal destruction with bone pain, pathological fractures and hypercalcemia. The other disease characteristics are anemia, renal failure, neurological complications and hyperviscosity syndrome. Most of the patients produce a monoclonal protein so-called paraprotein, M-protein or M-component, which is an immunoglobulin (Ig) or a fragment of one that has lost its function (1) . The normal immunoglobulin levels are compromised, leading to predilection to infections. The proliferated plasma cells displace the normal bone marrow architecture, which is reflected by clinical findings such as anemia, neurological symptoms and bone resorption seen as diffuse osteoporosis or lytic bone lesions (2) . Furthermore, hypercalcemia, renal impairment and detectable monoclonal protein in the serum and/or urine are frequently seen. A small minority of patients are non-secretory.
At the time of diagnosis, MM is a heterogeneous disease, with a course that varies on the basis of both disease and host-related factors (age, renal function, stage, chromosomal abnormalities etc.). Multiple myeloma causes significant morbidity and mortality. It accounts for approximately 1% of all malignancies and 13% of hematological cancers. Approximately 50000 patients per year are diagnosed with MM in EU and US, and 30000 patients per year die due to multiple myeloma (4, 5).
Treatment Approach
MM can cause many acute complications such as hyperviscosity syndrome, hypercalcemia, spinal cord compression, early infection, bone disease and renal impairment; some of them are life-threatening. The treatment of these medical emergencies has greatly decreased morbidity and early mortality in patients.
Hyperviscosity syndrome occurs in cases with high serum paraprotein levels, particularly those of IgA or IgG3 type. Symptoms include: blurred vision, headaches, mucosal bleeding and dyspnea due to heart failure. Symptomatic patients should be treated urgently with plasma exchange; isovolaemicvenesection may be useful if plasma exchange facilities are not immediately available. If transfusion is essential, exchange transfusion should be performed. Rapid reduction of protein levels is mandatory and anti-myeloma treatment should be instituted promptly. (6) .
Hypercalcemia occurs in about 30% of newly diagnosed patients. Acute hypercalcemia can present with central nervous system dysfunction (confusion, coma and obtundation), muscle weakness, pancreatitis, constipation, thirst, polyuria, shortening of the Q-T interval on ECG and even, acute renal failure. Mild hypercalcemia with calcium range from 2.6 -2.9mmol/l, may be corrected with oral and/or intravenous rehydration. Moderate and severe hypercalcemia with calcium range over 2.9mmol/l, requires intravenous rehydration with normal saline. Adequate urine output should be ensured and use of intravenous loop diuretics such as furosemide should be considered to avoid volume overload and heart failure and promote urinary calcium excretion. All patients with moderate to severe hypercalcemia should receive a bisphosphonate (zolendronic acid is the bisphosphonate of choice). Dental procedures, such as root canal or extraction of teeth, may be associated with infection or destruction of the jaw (osteonecrosis), so they should be performed before bisphosphonate treatment is started. Licensed Under Creative Commons Attribution CC BY disease), the spinal level, extend of the disease and the rate of development of cord compression and commonly include sensory loss, paresthesiae, limb weakness, walking difficulty and sphincter disturbance. Spinal cord compression is a medical emergency requiring rapid diagnosis and treatment to prevent irreversible damage, such as paralysis. Upon clinical suspicion for such a complication, Dexamethasone 40mg daily for 4 days should be commenced. MRI or at least CT scan should be immediately obtained. If there is a structural compression of spinal cord, it is necessary to perform urgent surgical decompression, usually followed by local radiotherapy (at the latest for 24 hours) with a dose of at least 30 Gy (8) . For soft tissue disease local radiotherapy is the treatment of choice and should be commenced urgently, preferably within 24 hours.
The early infection in patients with MM is related to deficits in both humoral and cellular immunity. It has been reported that up to 10% of patients die of infective causes early, within 60 days of diagnosis. It is recommended to treat every febrile patient with wide spectrum antibiotics. In case of severe, systemic infections or neuthropenic sepsis, parenteral antibiotics should be administrated but aminoglycosides should be avoided (9) .
Bone disease occurs in about 80-90% of patients with MM. It results in pain, pathological fractures with potential risk of cord compression and hypercalcemia. Skeletal events compromise mobility and independence of patients, decreasing quality of life. Long bone fractures are treated by immobilization and radiotherapy that can improve pain and promote healing of the fracture site. The recommended dose is 8 Gy for a single fracture. In case of larger lytic lesions of skeleton, an orthopedic surgeon should be consulted and in some patients a surgery with vertebroplasty or kyphoplasty should be done. Bisphosphonates have a favorable effect in controlling the bone lesions in patients with MM, even in those without bone disease at presentation. The duration of the treatment depends on individual factors such as: achieving remission, expressiveness of bone lesions, renal function (10) . It is reasonable to stop the treatment in patients who achieve complete response or a very good partial remission and who do not have active bone disease. It is mandatory to perform a good dental inspection always when bisphosphonate therapy is planned and to perform dental procedures such as root canal or extraction of teeth before these agents are started in order to prevent the most difficult complication-osteonecrosis of the jaw.
Renal failure is a frequent and potentially serious complication that occurs in 20-25% of patients at presentation and in nearly 50% of patients during the disease course. It is due to destruction of renal tubules from the serum free light chain ("myeloma kidney") but other factors such as dehidratation, hypercalcemia, application of nephrotoxic agents оr infections, also, contribute. Patients, who have renal failure at presentation, have high level of early fatal outcomes. For maintenance of a good renal function, patients are advised to stay well-hydrated, to drink enough fluids to produce three liters of urine daily and to avoid nephrotoxic agents including aminoglycosides and non-steroidal anti-inflammatory drugs (11).
Chemotherapeutical Protocols
Multiple myeloma can remain stable for prolonged periods of time. Individuals with early myeloma who have no symptoms (often called "smoldering" myeloma) may be advised to wait months to years before considering chemotherapy. Regular controls should be performed on 3 months intervals with quantifying serum and urinary Mprotein. Bone marrow examination and bone x-ray should be performed before initiating the chemotherapy. The chemotherapy is indicated for symptomatic myeloma in patients with ROTI (Myeloma related Organ or Tissue Impairment) or CRAB (Calcium levels increased, Renal failure, Anemia, Bone lesions).
The choice of treatment protocol depends on the age of the patient, performance status, aggressiveness of the disease and other prognostic factors (3). Newly diagnosed patients with MM are categorized in 2 subpopulations, usually depending on their age and the convenience for the following treatment. The younger patients should be treated with induction protocols that will be followed with consolidation with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Patients, who are not eligible for HDC and ASCT, should be treated with long-lasting therapy that includes combination of several medications (alkylating agents, high-dose corticosteroids and the new agents).
A. Induction therapy in patients not eligible for HDC
and ASCT The aim of this treatment is to achieve the maximum, durable response with minimal treatment-related toxicity. Oral MP protocol (Melphalan + Prednisolon) was utilized as a first line treatment from 1960-ies and for a long time remained a gold standard for treating patients not eligible for ASCT. Cyclophosphamide versus Melphalan asserted nearly identical results in 2 UK MRC trials. However, Melphalan was preferred because of its better tolerability in older population. More complex protocols including combination of several intravenous drugs were utilized afterwards. Nevertheless, a large meta-analysis of Myeloma Triallists` Collaborative Group from 1998, did not assert higher efficiency related to oral MP protocol (12, 13) .
Thalidomide is one of the first newly introduced agents for treatment of MM. It is one of the "immunomodulatory" agents that have several mechanisms of action: antiangiogenic effect, inhibition of tumor necrosis factor (TNF), secretion of interleukin 2 and induction of apoptosis of tumor cells. Thalidomide is an efficient agent in all phases of MM treatment. It can be used as a single agent therapy or in combination with steroids or other drugs. The study of Rajkumar et al., 2006 , phase III (14) compared TD (Thalidomide + Dexamethasone) protocol to Dexamethasone as a single-agent therapy in patients at middle age of 65 years. It demonstrated significant benefit in relation to response to therapy (overall response CR+PR) in 63% versus 46%.There was a benefit regarding the time to progression (TP) in TD group but also, grade 3 nonhematological toxicity in 67% of patients on TD protocol. (20) . CTD is now the most frequently used protocol in Great Britain because it does not affect the mobilization of stem cells. 
Conclusion
MM remains an incurable disease further more. However, the implementation of the new therapeutically protocols and the ASCT as well as the improvement in symptomatic and supportive care, contributed to enhance response to treatment, to prolong the event free survival and the overall survival and, what is most important, to improve the quality of life of these patients. 
